Phase 2
Completed N=14
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Source: ClinicalTrials.gov NCT03809078 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcomePrimary: Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings — 13; 13 Participants
Summary
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings |
13; 13 | — |
Eligibility Criteria
Inclusion Criteria
- Suspected prostate cancer
- Planned prostate biopsy
- Able to provide written consent
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
Exclusion Criteria
- Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Data sourced from ClinicalTrials.gov (NCT03809078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.